Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors

Summary

This is an open label, single arm, single center, phase 2 study with the use of the antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell tumors who are not cured following first or subsequent chemotherapy lines for metastatic disease, followed by eventual surgery.

Timeline

Start

2013-05-17

Primary completion

2016-07-27

Completion

2016-07-27

Drugs

Indications